Stanley-Laman Group’s MacroGenics MGNX Stock Holding History

Stanley-Laman Group’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22,381	Closed	-$462K	–	232
2018 Q2	$462K	Buy	+22,381	New	+$504K	0.1%	220

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Stanley-Laman Group's MGNX Position: Q3 2018 in Review

Stanley-Laman Group sold out of MacroGenics (MGNX) in Q3 2018, closing a stake of 22,381 shares — an estimated $462K sold.

Stanley-Laman Group first reported a position in MGNX in Q2 2018 and held it in 1 quarter. The position peaked at $462K in Q2 2018. 130 funds tracked by Wall St. Rank hold MGNX as of Q3 2018.

Stanley-Laman Group reported no remaining MacroGenics position as of Q3 2018 after selling out during the quarter.
Stanley-Laman Group sold 22,381 MacroGenics shares in Q3 2018, an estimated $462K.
Stanley-Laman Group first reported a position in MacroGenics in Q2 2018 and held it in 1 quarter.
Stanley-Laman Group's MacroGenics position peaked at $462K in Q2 2018.
130 funds tracked by Wall St. Rank held MacroGenics as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.